News &amp; Updates

Carpal tunnel syndrome (CTS) is not uncommon in patients being treated with anticancer therapeutic agents, reports a study. Electrodiagnostic (EDX) studies and ultrasound (US) are necessary in the diagnostic assessment of these individuals.

Patients on anticancer therapeutic agents may develop carpal tunnel syndrome

Low-dose oral midazolam not linked to improved patient satisfaction after surgery

Premedication with low-dose oral midazolam in older patients undergoing a surgical procedure falls short of improving perioperative patient satisfaction, according to a study.

Low-dose oral midazolam not linked to improved patient satisfaction after surgery

Acetylcholinesterase inhibitors may have potential protective effect against AMD

In the treatment of individuals with Alzheimer’s disease, acetylcholinesterase inhibitors (AChEIs) appear to confer a small reduction in the risk of age-related macular degeneration (AMD), as shown in a study.

Acetylcholinesterase inhibitors may have potential protective effect against AMD

TRT boosts sexual function, eases symptoms in men with hypogonadism

Testosterone replacement therapy (TRT) can help increase sexual activity, improve hypogonadal symptoms, and boost sexual desire among middle-aged and older men with hypogonadism and low libido, reports a study. However, TRT does not improve erectile function.

TRT boosts sexual function, eases symptoms in men with hypogonadism

22 Feb 2024

Immunogenicity does not affect pharmacokinetics, efficacy of tirzepatide

22 Feb 2024 by

Treatment-emergent (TE) antidrug antibodies (ADA) do not show any influence on the pharmacokinetics or efficacy of tirzepatide (TZP), as shown in a study. Most of the hypersensitivity or injection site reactions in patients with TE ADA are either mild or moderate in severity.

Immunogenicity does not affect pharmacokinetics, efficacy of tirzepatide

In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).

Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD

22 Feb 2024 by

Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD

22 Feb 2024

RNA interference with zilebesiran shows therapeutic potential in mild-to-moderate hypertension

Zilebesiran, an investigational RNA interference therapeutic agent that targets hepatic angiotensinogen synthesis, appears to have a promising blood pressure (BP)-lowering effect in adults with mild-to-moderate hypertension, according to the phase II KARDIA-1 trial.

RNA interference with zilebesiran shows therapeutic potential in mild-to-moderate hypertension

Patch test a boon to dupilumab-treated patients

A prospective, multicentre study has demonstrated the efficacy of patch tests (PTs) for patients who are being treated with dupilumab.

Patch test a boon to dupilumab-treated patients

COVID-19 shots offer durable protection in IBD population

Adults with inflammatory bowel disease (IBD) benefit from COVID-19 vaccination, with its protective effect lasting up to 52 weeks postvaccination even among vulnerable populations such as corticosteroid users and older individuals, according to a study.

COVID-19 shots offer durable protection in IBD population